Cargando…

Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study

BACKGROUND: Vedolizumab is increasingly used off-label to treat children and adolescents with inflammatory bowel disease (IBD). In the absence of rigorous clinical trial experience, multicenter observational data are important to establish expectations for efficacy and safety. We examined 1-year out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajjat, Temara M, Mosha, Maua, Whaley, Kaitlin G, Rosen, Michael J, Suppa, Carmine, Markowitz, James, Dufour, Lauren, Sauer, Cary, Shukla-Udawatta, Monica, Boyle, Brendan, Gibson, Meghan, Shapiro, Jason, Sams, Derica, Sylvester, Francisco, Hunter, Gabriele, Perez, Maria E, Hyams, Jeffrey S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802305/ https://www.ncbi.nlm.nih.gov/pubmed/36776669 http://dx.doi.org/10.1093/crocol/otab039

Ejemplares similares

Similar Long-Term Outcomes in Children Presenting With Abscess vs Phlegmon at Diagnosis of Crohn Disease
por: Fondell, Andrew W, et al.
Publicado: (2020)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
por: Uda, Akihito, et al.
Publicado: (2020)

CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease
por: Kwapisz, Lukasz, et al.
Publicado: (2022)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab
por: Chiorean, Michael, et al.
Publicado: (2020)

Real-World Effectiveness of Vedolizumab Dose Escalation in Patients With Inflammatory Bowel Disease: A Systematic Literature Review
por: Patel, Dipen, et al.
Publicado: (2022)

Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
por: Gagnon, Ann-Lorie, et al.
Publicado: (2021)

Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
por: Kappelman, Michael D, et al.
Publicado: (2023)

Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis
por: Ungaro, Ryan C, et al.
Publicado: (2022)

Probability of Response as Defined by a Clinical Decision Support Tool Is Associated With Lower Healthcare Resource Utilization in Vedolizumab-Treated Patients With Crohn’s Disease
por: Dulai, Parambir S, et al.
Publicado: (2022)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
por: Vande Casteele, Niels, et al.
Publicado: (2023)

Tumble Suppression Is a Conserved Feature of Swarming Motility
por: Partridge, Jonathan D., et al.
Publicado: (2020)

Widespread Strain-Specific Distinctions in Chromosomal Binding Dynamics of a Highly Conserved Escherichia coli Transcription Factor
por: Connolly, James P. R., et al.
Publicado: (2020)

Antimicrobial Susceptibility Testing for Three Malassezia Species
por: Rathie, Brooke, et al.
Publicado: (2023)

Hyperkeratotic necrobiosis lipoidica
por: Khan, Farhan, et al.
Publicado: (2013)

Histiocytoid Sweet’s syndrome in a patient with myelodsyplastic syndrome: report and review of the literature
por: Shalaby, Michael M., et al.
Publicado: (2016)

EARLY STRENGTH TESTING AFTER ACL RECONSTRUCTION IMPACTS ISOKINETIC STRENGTH PERFORMANCE AT TIME OF RETURN TO SPORT
por: Weaver, Adam, et al.
Publicado: (2021)

Comparative Genomic Study of Lactobacillus jensenii and the Newly Defined Lactobacillus mulieris Species Identifies Species-Specific Functionality
por: Putonti, Catherine, et al.
Publicado: (2020)

Assessing disease activity using the pediatric Crohn’s disease activity index: Can we use subjective or objective parameters alone?
por: Grant, Amy, et al.
Publicado: (2021)

Mindfulness Education for Otolaryngology Residents: A Pilot Study
por: Kashat, Lawrence, et al.
Publicado: (2020)

SARS-CoV-2 RNA Is Readily Detectable at Least 8 Months after Shedding in an Isolation Facility
por: Coil, David A., et al.
Publicado: (2022)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Analysis of the ARTIC Version 3 and Version 4 SARS-CoV-2 Primers and Their Impact on the Detection of the G142D Amino Acid Substitution in the Spike Protein
por: Davis, James J., et al.
Publicado: (2021)

Method comparison of beta‐hydroxybutyrate point‐of‐care testing to serum in healthy children
por: Parmar, Komalben, et al.
Publicado: (2021)

Improving Delivery of Care through Standardized Monitoring in Children with Eosinophilic Esophagitis
por: Shukla-Udawatta, Monica, et al.
Publicado: (2021)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Clinical Trials on Cellular Therapy for Children and Adolescents With Cancer: A 15-Year Trend in the United States
por: Cho, Sukjoo, et al.
Publicado: (2023)

Chronic Cholestatic Liver Injury Attributable to Vedolizumab
por: Stine, Jonathan G., et al.
Publicado: (2016)

A Case of Evan's Syndrome Induced by Vedolizumab
por: Jen, Henry, et al.
Publicado: (2019)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_99dbercsrbh8mmtsv0sacaml5n